Regulatory approval

Sanofi’s Tzield moves type 1 diabetes into disease modification, but access may decide who benefits

EMA backs first oral obesity GLP-1 as pills push treatment towards mass-market adoption

GSK’s Nuvalent Deal Turns Lung Cancer Precision Into a $10.6 Billion Access Race

The next cardiometabolic battleground is ultra-processed food

Hepatitis B Functional Cure Moves Closer, But Access Still Starts With Diagnosis

A Urine Test for Alzheimer’s Would Change the Access Conversation
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
